During glomerular vasodilation associated with obesity, podocytes detach and are shed into urine [1, 2, S1]. Although podocyte-associated mRNA has been previously found in the urine of morbidly obese patients, even at normal albuminuria levels [3], a marker for early renal damage is essential.
Analysis of podocalyxin has been used to detect podocytes [4] and vesicles [S2, S3], however this marker is not exclusive for this type of cells [5]. Moreover, podocin and nephrin mRNA have also been detected [1,S4,S5], but their clinical utility is clear[S6].
Here we present a pilot study to propose a new non-invasive method to determine the presence of podocytes in the urine of patients with obesity based on the detection of nephrin on the podocyte surface, their nuclear lamin A content, associated with the ratio between podocytes and total cells found in urine.
We collected 24 h urine samples from lean subjects and patients who were morbidly obese before surgery and obese one year after bariatric surgery (Fig. 1a). We used flow cytometry, measuring nephrin to detect podocytes, and lamin A to detect binucleated podocytes (Supplementary Methods). The different podocyte populations included mononucleated podocytes, small binucleated podocytes and large binucleated podocytes (Fig. S1).
Obese before surgery patients exhibit a higher concentration of binucleated podocytes compared to lean subjects (Fig S3). Contrary to our expectations, after bariatric surgery we observed that the urinary concentration of podocytes was increased compared to what was observed before surgery (Fig. S3). Even when we normalized for volume (Fig. S4) and mg of creatinine (Fig S5) in 24 h urine, we obtained similar results.
We then questioned the reliability of volume as a normalization factor in our samples. Therefore we normalized our podocyte populations with regard to the total number of cells found in 24 h urine samples. Although there were non-significant changes in the total podocyte/total cell ratio between obese patients before surgery and lean subjects, we observed a significant reduction after surgery compared to before surgery (Fig. 1a). This reduction was primarily due to changes in binucleated podocytes, and the binucleated podocyte/total cell ratio in urine was significantly higher in obese patients before surgery compared to lean subjects (Fig. 1d). However, after surgery patients exhibited a decrease in this ratio (Fig. 1d), which aligned more with the clinical status (Fig. 1a). These changes were not observed for mononucleated podocytes (Fig. 1c).
Several attempts have been made to detect early glomerular damage through analysis of the urine [5] using non-specific podocyte proteins [4, S2, S3, 5]. Previous studies have used podocalyxin-positive cells in urinary sediment from healthy individuals and patients to quantify podocyturia. However, these studies relied on a non-specific podocyte protein, and were conducted using spot urine samples, which were then extrapolated to 24 h [6, 7]. In our study, we propose a potentially more precise method for measuring podocyturia. We measured the podocyte-specific marker nephrin to detect podocytes [3]. Unlike previous approaches, our method is based on 24 h urine samples and utilizes counting beads as a quantitative tool.
We also observed that about half of the patients presented a reduction in the pathological binucleated/cell ratio after bariatric surgery, while the other half did not (Fig. 1d). Upon analyzing both groups, we found that those who experienced a reduction in the binucleated/cell ratio after bariatric surgery were younger and had fewer or less severe comorbidities (Table S1). We hypothesized that this could be attributed to the prolonged duration of complications associated with obesity in older patients. Kidney injury could have persisted for a longer period, resulting in a greater loss of podocytes before the measurements were performed. Consequently, podocyturia could potentially serve as an indicator for detecting early stages of glomerular injury caused by obesity.
Furthermore, we observed that both small binucleated podocyte/cell and large binucleated podocyte/cell ratios were significantly higher in obese patients before surgery compared to lean subjects, while they decreased after bariatric surgery (Fig. 1e and f). We hypothesized that the number of podocytes in after surgery patients may be lower due to the absence of active kidney damage (Fig. 1f). These findings are in agreement with previously observed data [8], leading us to propose this normalization approach.
After podocyte injury, karyokinesis occurs, leading to death through mitotic catastrophe [S7]. Detecting binucleated podocytes has been a challenging task with limited success [6, 7, S8]. In this study, we propose the use of lamin A as a marker for identifying binucleated podocytes. This choice is based on the fact that non-proliferating cells may lack lamin A expression [S9], and lamin A function has been found to be affected by genetic conditions known as laminopathies, which accelerate aging [S10]. Our findings indicate that the content of lamin A is possibly associated with the DNA content, suggesting that an increase in lamin A levels may indicate podocyte karyokinesis. Importantly, this increase does not appear to be linked to apoptosis in these cells. Taken together, these data support the use of lamin A as a tool for detecting glomerular injury through the identification of binucleated podocytes.
Podocyte markers have been detected in urine, but their concentrations are often very low and can be influenced by the confounding effect of urine concentration [5]. Our study suggests a protective effect of bariatric surgery one year after surgery [8], however this effect was not maintained after normalization for the podocyte concentration. This raises the question of whether we can rely on urine volume as a normalization factor [S11]. To address this issue, we propose a new method for normalizing podocyte numbers by considering the total cells in urine. This approach would allow us to use both spot or 24 h urine, enhancing flexibility in sample collection and analysis.
Our study’s primary limitation lies in the small size of our cohort and the difficulty in recruiting morbidly obese patients without diagnosed kidney damage. Therefore, it is crucial to confirm our results in a larger cohort and investigate other pathological conditions. Nevertheless, this protocol may be considered as a suggestion for exploring podocyturia.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
We would like to thank all our colleagues who donated their urine to calibrate the technique prior to the experiments.
Author contributions
AGC designed and performed the experiments; IGP, RV-B, MM-T and EM recruited patients and collected samples; AGC analyzed the data and made the figures; AGC, AIL, EM and GM-G revised the results; AGC drafted the manuscript; AGC, AI-L, EP, EM and GM-G revised the manuscript. All authors approved the final version of the manuscript.
Funding
The research presented in this work was supported by the Ministerio de Economía y Competitividad (Spain) (BFU2016-78951-R), Comunidad de Madrid (Spain) (B2017/BMD-3684, P2022/BMD-7227), Ministerio de Ciencia e Innovación (Spain) (PID2020-116875RB-I00, PDC2021-121871-I00) and Comunidad de Madrid/ Universidad Rey Juan Carlos (Proyecto I + D jóvenes doctores. Ref. A484 – EXOKID).
Declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Universidad Rey Juan Carlos (Numbers of registration 0811202121321, 01/21/2021 and ENM40/161911201814318, 08/09/2019) and the CEIC of Hospital 12 de Octubre (Number of registration 23/031, 12/01/2023).
Human and animal rights
The present study complies with the guidelines for human studies. This study does not contain any studies with animals.
Informed consent
Informed consent was obtained from all subjects involved in the study.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Adriana Izquierdo-Lahuerta, Email: adriana.izquierdo@urjc.es.
Gema Medina-Gómez, Email: gema.medina@urjc.es.
References
- 1.Lioudaki E, Stylianou KG, Petrakis I, Kokologiannakis G, Passam A, Mikhailidis DP, et al. Increased urinary excretion of podocyte markers in normoalbuminuric patients with diabetes. Nephron. 2015;131(1):34–42. doi: 10.1159/000438493. [DOI] [PubMed] [Google Scholar]
- 2.Yu D, Petermann A, Kunter U, Rong S, Shankland S, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16(6):1733–1741. doi: 10.1681/ASN.2005020159. [DOI] [PubMed] [Google Scholar]
- 3.Pereira SV, Dos Santos M, Rodrigues PG, Do Nascimento JF, Timm JRT, Zancan R, et al. Increased urine podocyte-associated messenger RNAs in severe obesity are evidence of podocyte injury. Obesity. 2015;23(8):1643–1649. doi: 10.1002/oby.21156. [DOI] [PubMed] [Google Scholar]
- 4.Suwanpen C, Nouanthong P, Jaruvongvanich V, Pongpirul K, Pongpirul WA, Leelahavanichkul A, et al. Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. J Nephrol. 2016;29(1):37–44. doi: 10.1007/s40620-015-0199-8. [DOI] [PubMed] [Google Scholar]
- 5.Zeng L, Szeto CC (2021) Urinary podocyte markers in kidney diseases. Vol. 523, Clinica Chimica Acta. Elsevier B.V., p. 315–24 [DOI] [PubMed]
- 6.Vogelmann SUS, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol-Renal Physiol [Internet] 285(1):F40–48. Available from: http://www.ajprenal.org [DOI] [PMC free article] [PubMed]
- 7.Larsen CP, Messias NC, Walker PD. B7–1 immunostaining in proteinuric kidney disease. Am J Kidney Dis. 2014;64:1001–3. doi: 10.1053/j.ajkd.2014.07.023. [DOI] [PubMed] [Google Scholar]
- 8.Lanzon B, Martin-Taboada M, Castro-Alves V, Vila-Bedmar R, González de Pablos I, Duberg D, Gomez P, Rodriguez E, Orešič M, Hyötyläinen T, Morales E, Ruperez FJ, Medina-Gomez G (2021) Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites 11(12):836. 10.3390/metabo11120836 [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.